《浆细胞样树突状细胞介导的HIV和脂多糖对CD27+IgD-记忆B细胞凋亡的协同效应》

  • 来源专题:艾滋病防治
  • 编译者: 门佩璇
  • 发布时间:2014-09-28
  •        在HIV感染中,严重的微生物异位对B细胞的影响目前尚不清楚。本研究开展了体外试验来评估HIV病毒和脂多糖(LPS)对CD27+IgD-记忆B细胞凋亡的影响。队列中有82名HIV阳性捐赠者和60名健康对照。在体外,单核细胞(PBMCs)暴露于LPS和HIV会通过Fas/FasL通路导致记忆B细胞(mB)死亡。感染HIV后,浆细胞样树突状细胞(pDCs)产生FasL与CD4和趋化因子结合。在pDCs和单核细胞存在的情况下,HIV和LPS会增加PBMCs 中mB Fas的表达。此外,从PBMCs中分离纯化,并用HIV和LPS预处理的mB对凋亡更加敏感。在pDCs中,阻止干扰素受体(IFNR)能够防止HIV刺激产生FasL,HIV与LPS介导的Fas表达,以及mB细胞的凋亡。无论在体内还是体外,HIV阳性捐赠者都比对照组具有更高的血浆LPS水平,mB细胞Fas表达水平和mB细胞凋亡水平。相应地,在HIV阳性者内,血浆FasL与HIV RNA水平呈正相关,mB细胞Fas表达和血浆LPS水平也呈正相关。该研究揭示了由LPS和HIV介导的通过Fas/FasL通路实现的mB细胞凋亡的全新机制,其中pDCs和I型干扰素发挥着关键性的作用。研究也揭示了之前未被发现的微生物易位在HIV感染发病机制中所扮演的重要角色。

相关报告
  • 《树突状细胞交叉呈递活的和凋亡的CD4+ T细胞的HIV抗原》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2005-04-15
    • A better understanding of the antigen presentation pathways that lead to CD8+ T cell recognition of HIV epitopes in vivo is needed to achieve better immune control of HIV replication. Here, we show that cross-presentation of very small amounts of HIV proteins from apoptotic infected CD4+ T lymphocytes by dendritic cells to CD8+ T cells is much more efficient than other known HIV presentation pathways, i.e., direct presentation of infectious virus or cross-presentation of defective virus. Unexpectedly, dendritic cells also take up actively antigens into endosomes from live infected CD4+ T lymphocytes and cross-present them as efficiently as antigens derived from apoptotic infected cells. Moreover, live infected CD4+ T cells costimulate cross-presenting dendritic cells in the process. Therefore, dendritic cells can present very small amounts of viral proteins from infected T cells either after apoptosis, which is frequent during HIV infection, or not. Thus, if HIV expression is transiently induced while costimulation is enhanced (for instance after IL-2 and IFN immune therapy), this HIV antigen presentation pathway could be exploited to eradicate latently infected reservoirs, which are poorly recognized by patients' immune systems.
  • 《母细胞性浆细胞样树突状细胞肿瘤新药Elzonris获得FDA批准》

    • 来源专题:重大新药创制—研发动态
    • 编译者:杜慧
    • 发布时间:2019-11-04
    • FDA批准了Stemline Therapeutics公司的Elzonris,用于母细胞性浆细胞样树突状细胞肿瘤(BPDCN)治疗。BPDCN是一种罕见的侵袭性骨髓和血液疾病,可以影响多个器官,包括淋巴结和皮肤,它通常表现为白血病或进展为急性白血病。FDA批准本品是基于一项多中心的单臂临床试验(NCT 02113982)的数据,受试者被分成了两个亚组,亚组一的13名患者均为初治型BPDCN,经过本品的治疗,7名患者(54%)达到完全缓解(CR)或皮肤异常并未表明活动性疾病的完全缓解(CRc);亚组二的15名患者则均为复发或难治性BPDCN,经过本品的治疗,一名患者达到CR,一名患者达到CRc。在本品之前,FDA并批准专门针对BPDCN的药物,因此本品获得了突破性疗法、优先审评和孤儿药三项认定。